Oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) announced better-than-expected revenue in Q3 2026, with sales up 11.4% year on year to $209.3 million. The company expects the full year’s revenue to be around $808 million, close to analysts’ estimates. Its non-GAAP profit of $0.07 per share was 26.2% above analysts’ consensus estimates.
Is now the time to buy NEO? Find out in our full research report (it’s free for active Edge members).
NeoGenomics (NEO) Q3 2026 highlights:
- Revenue $209.3 million vs S&P analysts’ estimates of $206.9 million (11.4% year-on-year growth, 1.1% beat)
- Adjusted EPS $0.07 vs S&P analysts’ estimates of $0.06 (26.2% beat)
- Adjusted EBITDA $18.67 million vs analyst estimates of $15.83 million (8.9% margin, 17.9% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $808 million at the midpoint from $804 million
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $0.22 at the midpoint, a 16.2% increase
- EBITDA guidance $60 million at the midpoint for the full year, above analyst estimates of $57.3 million
- Operating margin -3.8%, up from -14.4% in the same quarter last year
- Market capitalization $2.31 billion
StockStory’s take
NeoGenomics delivered an 11.4% year-over-year revenue increase in Q3, surpassing Wall Street’s expectations. Management emphasized that clinical revenue growth was primarily fueled by strong adoption of next-generation sequencing (NGS) tests and ongoing improvements in average price per test, aided by a strategic shift away from low-margin, high-volume contracts. CEO Anthony Zook highlighted that “NGS revenue grew a strong 29%,” attributing margin expansion to a higher mix of advanced tests and operational efficiency initiatives. Discipline in operating expenses and investment in infrastructure also supported profitability gains during the period.
Looking ahead, NeoGenomics outlined that continued expansion in NGS and minimal residual disease (MRD) testing, alongside operational improvements, are key to its updated guidance. Management expects further reimbursement wins and expanded sales efforts to support durable revenue growth and margin improvement. President Warren Stone, who will become CEO in January, stated, “Our focus areas remain consistent—delivering durable NGS growth, driving MRD uptake with RaDaR ST, and investing in our business while driving profitability through operational excellence.” The company plans to build on its portfolio momentum and capitalize on its position in the community oncology market.
Key insights from management’s remarks
Management attributed the quarter’s performance to durable growth in advanced clinical testing, improved product mix, and ongoing operational discipline, while the leadership transition aims to maintain continuity in strategy and execution.
- NGS test adoption accelerated: Next-generation sequencing (NGS) saw 29% revenue growth and 17% volume growth, driven by new product launches and a shift toward higher-value large panel tests. This adoption was supported by new therapies in hematology and greater uptake of the PanTracer test family in solid tumors.
- MRD launch gained traction: RaDaR ST, NeoGenomics’ minimal residual disease test, benefited from newly secured Medicare coverage for immunotherapy monitoring, with additional reimbursement indications under review. Over 30% of RaDaR ST orders were attached to other NeoGenomics tests, highlighting early multi-product adoption.
- Operational improvements boosted margins: Adjusted gross margin expanded over 300 basis points year-over-year, credited to a higher proportion of advanced tests, improved average unit price, and efficiency gains from Lab of the Future initiatives. Management noted continued investments in digital upgrades and laboratory automation.
- Leadership transition planned from strength: CEO Anthony Zook will become Executive Chair as Warren Stone, current President and COO, is promoted to CEO. Management emphasized that the transition is occurring while the business is performing well, ensuring strategic continuity.
- Nonclinical business remains a headwind: While the oncology data solutions (ODS) business showed potential, legacy pharma services continued to decline, prompting management to focus on higher-value opportunities and further portfolio rationalization to support long-term growth and profitability.
Drivers of future performance
NeoGenomics’ outlook centers on expanding advanced testing adoption, operational efficiency, and reimbursement progress, while investing in high-growth areas and navigating industry headwinds.
- NGS and MRD growth priorities: Management expects next-generation sequencing and RaDaR ST MRD test adoption to continue as main revenue drivers, supported by expanded sales resources, portfolio upgrades, and further reimbursement wins. The company anticipates that over time, these segments could represent up to two-thirds of clinical revenue.
- Margin expansion and efficiency: Ongoing investments in laboratory automation, digital infrastructure, and the NovaSeq X sequencing platform are projected to deliver further gross margin gains. Management believes these improvements, along with disciplined operating expense management, will help offset pricing pressures and regulatory headwinds such as PAMA rate adjustments.
- Portfolio rationalization and payer dynamics: NeoGenomics plans to further exit low-margin contracts and focus on its high-value oncology data and pharma services. While exposure to government pricing changes is limited, the company is closely monitoring reimbursement rates and expects continued commercial payer gains to support average price per test.
Catalysts in upcoming quarters
In the coming quarters, the StockStory team will focus on (1) the pace of RaDaR ST reimbursement expansion and its impact on MRD test adoption, (2) sustained double-digit growth in NGS volumes and the effect of portfolio upgrades, and (3) measurable improvements in gross margin from ongoing Lab of the Future investments. Monitoring execution of planned sales force expansions and integration of digital pathology and AI initiatives will also be key signs of progress.
NeoGenomics currently trades at $18.00, in line with $17.99 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
Now could be the perfect time to invest in these stocks
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
